See the DrugPatentWatch profile for Levetiracetam
Levetiracetam API Suppliers and Manufacturing
Levetiracetam, an antiepileptic drug, is manufactured by various active pharmaceutical ingredient (API) suppliers globally. These suppliers provide the raw chemical compound used in the formulation of finished drug products.
Who Makes Levetiracetam API?
Several companies are involved in the production of levetiracetam API. These include both large pharmaceutical manufacturers and specialized API producers. Key players in this market often have a presence in both established and emerging pharmaceutical manufacturing regions. Information on specific suppliers can be found through industry databases and trade associations. For a comprehensive list and details on API suppliers, resources such as DrugPatentWatch.com can be valuable [1].
What is the Difference Between Levetiracetam API and the Finished Drug?
The levetiracetam API is the pure, unformulated chemical substance that has the therapeutic effect. The finished drug product, such as tablets or oral solutions, contains the levetiracetam API along with inactive ingredients called excipients. These excipients help in the manufacturing process, improve stability, control the release of the drug, and enhance patient compliance. The API is the core active component, while the finished drug is the final dosage form ready for patient use [2].
How is Levetiracetam API Regulated?
The manufacturing and supply of levetiracetam API are subject to strict regulatory oversight by health authorities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality, safety, and purity of the API. Regulatory filings, such as Drug Master Files (DMFs), are often submitted to health authorities by API manufacturers to detail their manufacturing processes and quality controls [3].
What Factors Affect Levetiracetam API Pricing?
The pricing of levetiracetam API can be influenced by several factors. These include the cost of raw materials, manufacturing complexity, economies of scale, regulatory compliance costs, and market demand. Competition among API suppliers also plays a significant role in price determination. The development of generic versions of levetiracetam has led to increased competition and, consequently, can impact API pricing [4].
When Does Levetiracetam Patent Protection End?
Patent protection for levetiracetam has largely expired in many major markets, allowing for the production and sale of generic versions. The original patent for levetiracetam (Keppra®) was held by UCB Pharma. The expiration of these primary patents opened the door for generic manufacturers to enter the market. Details on patent expiry dates for specific regions and formulations can be found through patent databases and specialized resources like DrugPatentWatch.com [1][5].
Can Biosimilars Be Made for Levetiracetam?
Levetiracetam is a small molecule drug, not a biologic. Therefore, the concept of "biosimilars" does not apply. Biosimilars are highly similar versions of complex biologic medicines, typically proteins, derived from living organisms. Levetiracetam is produced through chemical synthesis, and its generic versions are identical copies of the original molecule, not biosimilars [2].
What are the Risks Associated with Levetiracetam API Sourcing?
Sourcing levetiracetam API involves several potential risks for drug manufacturers. These include ensuring consistent quality and purity from suppliers, managing supply chain disruptions, and adhering to evolving regulatory requirements. Dependence on a single supplier can also pose a risk. Drug manufacturers often mitigate these risks by qualifying multiple suppliers, conducting thorough quality audits, and maintaining robust inventory management [3].
Sources:
[1] DrugPatentWatch.com
[2] FDA.gov
[3] EMA.europa.eu
[4] PharmaManufacturing.com
[5] UCB.com